Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.71 |
| ▸ | CTSS | P25774 | 5/20 | 0.71 |
| ▸ | PPARA | Q07869 | 5/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181775 | 1.00 | CTSK (0.71) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL181808 | 1.00 | CTSK (0.71) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL8238590 | 0.95 | PPARA (0.70) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL13744253 | 0.95 | PPARA (0.70) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL344068 | 0.93 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL22651626 | 0.93 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL19605638 | 0.93 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL2781406 | 0.92 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL1374859 | 0.92 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL346311 | 0.92 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-5206235-A | Animal growth regulators; stimulants | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0480969-A4 | AMINO ACID ANALOG CCK ANTAGONISTS | — | 1993-01-07 | — | — | EP | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5149795-A | Fungicides | BAYER AG (DE) | 1992-09-22 | — | — | US | disclosed |
| EP-0480969-A1 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | disclosed |
| EP-0478362-A2 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| US-5019560-A | Method for treating fungal infections with nikkomycin derivatives | BAYER AG (DE) | 1991-05-28 | — | — | US | disclosed |
| WO-1991000725-A2 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
| EP-0367954-A1 | Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | CTSK 2131/4885CTSS 517/4885PPARA 740/4885 |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | FNTA, SF3B1, SF3A1 | CTSK 3833/4885CTSS 3207/4885PPARA 1562/4885 |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | CTSK 3919/4885CTSS 3313/4885PPARA 1389/4885 |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | CTSK 4487/4885CTSS 4120/4885PPARA 4497/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSK 485/4885CTSS 439/4885PPARA 4706/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSK 436/4885CTSS 379/4885PPARA 4696/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | CTSK 4676/4885CTSS 4503/4885PPARA 3778/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | CTSK 303/4885CTSS 714/4885PPARA 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.